ASH 2023 | First-in-human trial of NX-2127 in patients with R/R B-cell malignancies
Although BTK inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL) and certain subtypes of non-Hodgkin lymphoma (NHL), resistance to these agents occurs in many patients. In this video, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, shares insights into the mechanism of action of BTK degraders, and discusses the results of a Phase I study evaluating NX-2127 in patients with CLL and NHL (NCT04830137). This agent was well tolerated, with no significant adverse events (AEs) observed. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: MEI, Lilly Oncology, Nurix, Abbvie, Beigene, Janssen, Astra Zeneca, Bristol Meyers Squibb, Genentech, GenMab, Merck
Research Funding: MEI, Lilly Oncology, Cyclacel, Bayer, Nurix, Abbvie, Beigene, Astra Zeneca, Bristol Meyers Squibb, GenMab
